PDX Model Cohort
NSCLC PDX Models
An extensive bank of Non-Small Cell Lung Cancer - NSCLC PDX Models directly established from patients with late-stage NSCLC with smoking history, and pretreated patient tumors available for drug development research
Summary
Champions Oncology offers 179* clinically relevant Non-Small Cell Lung Cancer -NSCLC PDX models for oncology studies and drug development. These models are derived from late-stage NSCLC patients, many with smoking histories and prior treatment with Standard of Care therapies. They encompass a broad range of targetable mutations, including a unique EGFR triple-mutant model (CTG-3970). A significant number of the models have been extensively characterized, with 166* having Whole Exome Sequencing (WES), 158* RNA-seq, and 155* having both, along with in vivo drug response data. This comprehensive dataset enables robust exploration of biomarkers associated with response and non-response in NSCLC. More details on these models can be accessed via Champions’ Model Select®.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading NSCLC PDX Models cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history.
Access to one of the largest bank of NSCLC PDX models with clinically relevant molecularand pathological characteristics on the market.
Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
Includes models pretreated with advanced therapies like checkpoint inhibitors and EGFR-targeted treatments.
Clinically Relevant Models
Living & diverse bank of clinically relevant models that correlate with clinical outcomes
Ships within 24 hours